Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karl Swedberg

Showing results (291-300 of 471) with videos related to

Pageof 48
Sort By:
Journal of Cardiovascular Medicine (Hagerstown, Md.)|June 8, 2012
Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairmentMuthiah Vaduganathan, Mihai Gheorghiade, Peter S Pang, et al.
European Heart Journal|June 7, 2014
The importance of patient-reported outcomes: a call for their comprehensive integration in cardiovascular clinical trialsStefan D Anker, Stefan Agewall, Martin Borggrefe, et al.
Journal of the American College of Cardiology|July 3, 2007
Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke DatabankG Michael Felker, Larry A Allen, Stuart J Pocock, et al.
The New England Journal of Medicine|September 2, 2014
Angiotensin-neprilysin inhibition versus enalapril in heart failureJohn J V McMurray, Milton Packer, Akshay S Desai, et al.
Journal of Hypertension|October 5, 2019
Visit-to-visit blood pressure variation and outcomes in heart failure with reduced ejection fraction: findings from the Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms trialLuca Monzo, João Pedro Ferreira, Paula Abreu, et al.
Heart Rhythm|July 5, 2015
A novel method to predict the proportional risk of sudden cardiac death in heart failure: Derivation of the Seattle Proportional Risk ModelRamin Shadman, Jeanne E Poole, Todd F Dardas, et al.
European Journal of Heart Failure|May 12, 2015
Length of hospital stay and 30-day readmission following heart failure hospitalization: insights from the EVEREST trialHassan Khan, Stephen J Greene, Gregg C Fonarow, et al.
American Heart Journal|April 29, 2006
Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trialJohn J V McMurray, James B Young, Mark E Dunlap, et al.
ESC Heart Failure|October 10, 2018
Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas' cardiomyopathy Comment on: "Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial" by Bocchi et alFelix J A Ramires, Felipe Martinez, Efraín A Gómez, et al.
JAMA|October 13, 2005
Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failureCatherine Demers, John J V McMurray, Karl Swedberg, et al.
Pageof 48

Showing results (291-300 of 471) with videos related to

Sort By:
Pageof 48
Journal of Cardiovascular Medicine (Hagerstown, Md.)|June 8, 2012
Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairmentMuthiah Vaduganathan, Mihai Gheorghiade, Peter S Pang, et al.
European Heart Journal|June 7, 2014
The importance of patient-reported outcomes: a call for their comprehensive integration in cardiovascular clinical trialsStefan D Anker, Stefan Agewall, Martin Borggrefe, et al.
Journal of the American College of Cardiology|July 3, 2007
Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke DatabankG Michael Felker, Larry A Allen, Stuart J Pocock, et al.
The New England Journal of Medicine|September 2, 2014
Angiotensin-neprilysin inhibition versus enalapril in heart failureJohn J V McMurray, Milton Packer, Akshay S Desai, et al.
Journal of Hypertension|October 5, 2019
Visit-to-visit blood pressure variation and outcomes in heart failure with reduced ejection fraction: findings from the Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms trialLuca Monzo, João Pedro Ferreira, Paula Abreu, et al.
Heart Rhythm|July 5, 2015
A novel method to predict the proportional risk of sudden cardiac death in heart failure: Derivation of the Seattle Proportional Risk ModelRamin Shadman, Jeanne E Poole, Todd F Dardas, et al.
European Journal of Heart Failure|May 12, 2015
Length of hospital stay and 30-day readmission following heart failure hospitalization: insights from the EVEREST trialHassan Khan, Stephen J Greene, Gregg C Fonarow, et al.
American Heart Journal|April 29, 2006
Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trialJohn J V McMurray, James B Young, Mark E Dunlap, et al.
ESC Heart Failure|October 10, 2018
Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas' cardiomyopathy Comment on: "Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial" by Bocchi et alFelix J A Ramires, Felipe Martinez, Efraín A Gómez, et al.
JAMA|October 13, 2005
Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failureCatherine Demers, John J V McMurray, Karl Swedberg, et al.
Pageof 48